Bayer’s Supreme Court Win Opens the Door to a $7.25 Billion Settlement — and a Cash Drain That Won’t Quit

The US Supreme Court handed Bayer a historic 7-2 victory on June 25, stripping thousands of glyphosate lawsuits of their legal foundation. But the euphoria that propelled the stock 22% higher in seven days must now contend with a sobering reality: the company has tabled a $7.25 billion settlement offer to close out remaining claims, and its balance sheet is bleeding cash.

The ruling affirms that federal pesticide labeling rules trump state-level warnings, meaning California and other states cannot require cancer labels on products the EPA deems safe. That kills the “failure-to-warn” claims that formed the backbone of the Roundup litigation. To draw a line under the saga, Bayer has proposed a fresh $7.25 billion settlement, on top of more than $10 billion already paid out globally. Whether plaintiffs’ lawyers accept the deal will determine how quickly the company can turn the page.

Investors have already priced in a measure of relief. The shares closed Monday at €45.86 and continued to climb, touching €47.16 by Tuesday. The Relative Strength Index has surged to 78.4, well into overbought territory, and the stock now trades roughly 24% above its 200-day moving average of €36.77. The annualized volatility of nearly 58% underscores the market’s lingering nervousness. A near-88% climb from last August’s 52-week low of €25.09 suggests the rally has legs, but technical exhaustion is a real risk.

Should investors sell immediately? Or is it worth buying Bayer?

That risk is amplified by Bayer’s financial fundamentals. In the first quarter of this year, free cash flow was negative €2.3 billion, with roughly €2 billion of that consumed by litigation expenses. Net financial debt stands at €32.5 billion, and the company expects a further €5 billion in cash outflows this year for ongoing legal proceedings. The settlement offer — if accepted — would add another $7.25 billion in liabilities, leaving little room for growth investments despite the legal tailwind from Washington.

Management is racing to rebuild the drug pipeline as patent protection on the blockbuster anticoagulant Xarelto erodes. The FDA in May accepted Bayer’s application for accelerated review of the factor XIa inhibitor Asundexian, following positive Phase III data from the OCEANIC-STROKE study. Separately, the company struck a collaboration with US biotech Iambic Therapeutics to deploy AI in early-stage drug discovery. Both moves aim to fill the revenue gap left by Xarelto’s decline, but both will take years to bear fruit.

The litigation cloud, while lifted in part, has not fully cleared. The International Agency for Research on Cancer still classifies glyphosate as “probably carcinogenic,” keeping the political and regulatory debate alive. Bayer’s legal victory is procedural, not scientific.

All eyes now turn to August 7, when the company releases its second-quarter results. The market will be watching for signs that free cash flow is turning positive and that debt reduction is accelerating. Until then, the stock’s next move hinges on whether the $7.25 billion settlement offer is sealed — and whether the balance sheet can absorb it.

Ad

Bayer Stock: New Analysis - 30 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER’S | boerse | 69659796 |